Publicaciones en colaboración con investigadores/as de University Hospital Heidelberg (1)

2022

  1. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial

    Journal for immunotherapy of cancer, Vol. 10, Núm. 8